Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome

Obesity Clinical Trial

Official title:

Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03542240
• Other study ID #: HM20012060
• Status: Completed
• Phase: N/A
• Start date: September 19, 2018
• Est. completion date: November 13, 2020

Study information

• Verified date: January 2021
• Source: Virginia Commonwealth University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will investigate the effects of curcumin on the structure/function of the body by investigating whether targeted improvement of intestinal barrier function by supplementation with oral curcumin will result in attenuation of lipopolysaccharide (LPS) translocation and/or intestinal inflammation.

Description:

A typical diet in the United States, also known as Western diet, is very high in sugars and saturated fat, and poor in food such as fruits, vegetables, fish and whole grains. This type of diet is associated with higher risk to develop obesity and other health problems such as high blood pressure, high cholesterol, Type 2 diabetes, and heart disease. Western diet can also cause changes in the gut that allow bacteria that are typically only present in the gut to leak out into the bloodstream. It is thought that having gut bacteria in the bloodstream may play a role in the development of diseases like Type 2 diabetes and heart disease. Curcumin is a dietary supplement that comes from the root of the turmeric plant, and it may have an effect on the function of the gut and the leakage of gut bacteria into the bloodstream. The purpose of this research study is to evaluate the effects of daily curcumin dietary supplements on the function of the gut in subjects who are at risk for cardiovascular and metabolic diseases, for example they have increased blood pressure, increase waist circumference and high triglycerides (fat in the blood).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: November 13, 2020
• Est. primary completion date: November 13, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Based on National Institutes of Health (NIH) definition of Metabolic syndrome, the subject must meet at least 3 of the following criteria: A. Waist Circumference: Female = 88 cm, Male = 102 cm B. Blood Pressure: = 130/85 mm/Hg and/or treatment with blood pressure lowering medication C. Impaired fasting glucose or HbA1c (fasting glucose = 100 mg/dl or HgA1c = 5.7 D. HDL-C: Females< 50 mg/dl, Males < 40 mg/dl E. Triglycerides = 150 mg/dl

2. Willing and able to comply with the study protocol

Exclusion Criteria:

1. Diabetes

2. Established cardiovascular disease

3. Pre-existing liver disease other than NAFLD

4. Chronic kidney disease (Stage 4 and 5)

5. Rheumatological disease

6. Active malignancy

7. Alcohol consumption greater than 7 drinks per week for females and greater than 14 drinks per week for males

8. Current use of metformin and/or steroids

9. Curcumin supplementation

10. Females of child-bearing potential (NOT of child-bearing potential is defined as s/p hysterectomy or post-menopausal.)

11. Prisoners/wards of the state and individuals with limited English proficiency

Related Conditions & MeSH terms

• Heart Diseases
• High Blood Pressure
• High Cholesterol
• Hypercholesterolemia
• Hypertension
• Metabolic Syndrome
• Obesity
• Type2 Diabetes

Intervention

Dietary Supplement:
• Curcumin
500 milligram daily supplement

Locations

Country	Name	City	State
United States	Virginia Commonwealth University	Richmond	Virginia

Sponsors (1)

Lead Sponsor	Collaborator
Virginia Commonwealth University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change inintestinal permeability	Measured by level plasma lipopolysaccharide (LPS). A reduction in LPS suggests a reduction in intestinal permeability	Baseline to 12 months
Primary	Change in intestinal barrier function	Measured by level of excreted Zonulin in stool samples. A reduction in Zonulin suggests a reduction in intestinal barrier function	Baseline to 12 months